Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.

Pharmacogenomics - 1 Sept 2009

Daily Elizabeth B, Aquilante Christina L

Abstract excerpt

Cytochrome P450 (CYP) 2C8 is responsible for the oxidative metabolism of many clinically available drugs from a diverse number of drug classes (e.g., thiazolidinediones, meglitinides, NSAIDs, antimalarials and chemotherapeutic taxanes). The CYP2C8 enzyme is encoded by the CYP2C8 gene, and several common nonsynonymous polymorphisms (e.g., CYP2C8*2 and CYP2C8*3) exist in this gene. The CYP2C8*2 and *3 alleles have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Antimalarials
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C8

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hypoglycemic Agents

Share to Oxidation-Reduction

Share to Pharmaceutical Preparations

Source

Open in PubMed Open full text

Identifiers

PMID: 19761371
DOI: 10.2217/pgs.09.82
PMCID: PMC2778050

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies.PMID 19761371Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Cytochrome P450 in Pharmacogenetics: An Update.Semantic proximity Read ↗

Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.Semantic proximity Read ↗

Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance.Semantic proximity Read ↗

Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation.Semantic proximity Read ↗

Polymorphism of human cytochrome P450 enzymes and its clinical impact.Semantic proximity Read ↗

Cytochrome P450 2C8: Substrates, inhibitors, pharmacogenetics, and clinical relevanceSemantic proximity Read ↗

[Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].Semantic proximity Read ↗

Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review.Semantic proximity Read ↗

Cytochrome P450: Polymorphisms and Roles in Cancer, Diabetes and AtherosclerosisSemantic proximity Read ↗

Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms.Semantic proximity Read ↗

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.